Introduction {#s1}
============

A large number of drugs have the undesirable side effect of prolonging cardiac repolarization which can trigger life-threatening cardiac arrhythmias ([@bib18]). A typical cause is the inhibition of the inward rectifying potassium channel (hERG or *human ether-a-go-go* related gene encoded by *KCNH2*) ([@bib18]; [@bib43]), which results in the prolongation of the repolarization time and induces an increase of the QT interval on the electrocardiogram. The early prediction of drug-induced long QT (diLQT) is a major requirement to avoid exposing patients to cardiac arrhythmias and ultimately sudden cardiac death ([@bib47]). Eventually, diLQT is a major cause of drug withdrawal or of premature termination during development ([@bib11]). Regulatory agencies require that new drug candidates be systematically screened for hERG inhibition in animal models or in heterologous over-expression cellular systems ([@bib46]). Because of species-dependent differences of cardiac electrophysiology and the failure of heterologous systems to express all cardiac proteins, hERG screening however remains suboptimal and has a poor positive predictive value for subsequent proarrhythmia risk ([@bib13]; [@bib14]; [@bib46]).

The risk of developing diLQT varies markedly between subjects. Previous studies in the general population have shown that a small proportion (i.e., less than 10%) of patients exposed to QT-prolonging drugs actually develop diLQT ([@bib1]; [@bib18]; [@bib51]). Different observations support the existence of a genetic determinism to diLQT including the higher propensity to develop drug-induced repolarization abnormalities in first-degree relatives of patients with diLQT ([@bib19]) and the similarity to the congenital form of the long QT syndrome (LQTS), a rare inherited cardiac disorder ([@bib33]). Multiple rare mutations with marked effects in genes encoding ion channels have been reported to underlie LQTS ([@bib5]). However, candidate gene screening studies in large cohorts of patients with diLQT have reported a small prevalence (from 10 to 15%) of these mutations in the known LQTS genes ([@bib38]; [@bib57]). QT prolongation can be induced by mutations in many genes that occupy a substantial region of the human interactome and contain many drug targets ([@bib2]). The factors leading to diLQT in some individual subjects remain largely unclear but are probably driven by the additive effect of common genetic variants that reduce the cardiac repolarization reserve ([@bib1]; [@bib19]; [@bib42], [@bib44]). As a consequence, diLQT is difficult to predict as it usually develops in individuals with a predisposing genetic makeup which favors exaggerated response to a pharmacological challenge with QT-prolonging drugs ([@bib18]; [@bib44]) but does not affect cardiac repolarization features at baseline ([@bib1]; [@bib18]; [@bib47]).

Human induced pluripotent stem cells (iPSCs) have recently been proposed to model monogenic disorders including congenital LQTS ([@bib17]; [@bib32]; [@bib49]). Cardiomyocytes derived from congenital LQTS patient-specific iPSCs lines typically exhibit significant electrophysiological abnormalities due to the deficient function of some key cardiac ion channels ([@bib17]; [@bib32]). These cells display increased arrhythmogenicity under native conditions and can be used as a test system for customization of anti-arrhythmic drugs in these patients ([@bib52]; [@bib56]). In addition, QT prolonging drugs can trigger changes in the electrical potential developed by iPSC-derived cardiomyocytes (iPSC-CMs) ([@bib25]; [@bib35]; [@bib36]).

To expand upon these observations, our goal was to determine whether iPSC-CMs from a group of subjects with quantitative measure of diLQT in vivo could recapitulate the phenotype in vitro thereby providing a model system for diLQT. In this study, we show that iPSC-CMs from subjects shown to be susceptible to diLQT in vivo but otherwise normal present no abnormalities in their basal characteristics but higher cardiotoxic responses to drug stimulation as compared to control iPSC-CMs. The contrasted responses to sotalol in iPSC-CMs were strongly correlated to the inter-individual differences in response to sotalol as recorded during clinical investigations. Our findings offer novel insights on the use of a genetically diverse panel of induced pluripotent stem cells to model complex pharmacogenetic traits.

Results {#s2}
=======

Identification of subjects susceptible to develop drug-induced long QT {#s2-1}
----------------------------------------------------------------------

We first performed a clinical study (clinicaltrials.gov NCT01338441) where we prospectively evaluated cardiac repolarization of healthy subjects in response to a pharmacological challenge with a single 80 mg oral dose of sotalol. Sotalol is a non-selective competitive β-adrenergic receptor blocker with additional Class III antiarrhythmic properties by its inhibition of potassium channels ([@bib58]). Sotalol is widely recognized as a classical QT-prolonging drug ([@bib51]). A total of ninety-two subjects were enrolled in the study ([Figure 1A](#fig1){ref-type="fig"}). All subjects gave their written informed consent to participate the study. Included subjects were aged from 18 to 40 years (30.1 ± 6.2 years), had a body mass index (BMI) between 19 and 29 kg/m² (23.9 ± 2.3 kg/m²), were from Caucasian origin and had no known significant disease or long-term treatment. Forty-four percent (n = 40) were male. Cardiac repolarization parameters were analyzed through standardized measurements of digital high-resolution ECG (sampling rate 1000 Hz). All subjects had a normal sinus rhythm and no significant conduction or repolarization abnormalities. Basal QT interval ranged from 340 to 458 ms (393.4 ± 26.3 ms), with a corresponding heart rate ranging from 47 to 88 bpm (63.3 ± 8.7 bpm). QT interval was corrected according to Fridericia\'s formula (QTcf=QT/\[RR\]^1/3^) providing corrected QTcf in the physiological range from 350 to 447 ms (399.0 ± 18.6 ms). Three hours after sotalol intake, QTcf had increased by 23.4 ± 2.4 ms. A large inter-individual variability was however noticed with a change in QTcf ranging from −9 ms to +81 ms and a resulting post-sotalol QTcf ranging from 351 to 489 ms (412.6 ± 43.0 ms) ([Figure 1B](#fig1){ref-type="fig"}).10.7554/eLife.19406.003Figure 1.QTcf changes following Sotalol administration in healthy volunteers.(**A**) Flow chart of the clinical study. (**B**) Distribution of QTcf duration before (blue) and 3 hr after sotalol intake (red). (**C**) Distribution of delta change in QTcf showing the wide inter-individual variability in response to the same pharmacological stimulation. Subjects with the most extreme responses were selected as low sensitive (low-S) or high- sensitive (high-S) as indicated in green and red respectively. (**D**) Average delta change in QTcf in the two groups of selected subjects. \*\*\*p\<0.001. (**E**) Typical ECG recordings before and after sotalol intake in a high-S subject (upper panels) and in a low-S subject (lower panels). There is one figure supplement.**DOI:** [http://dx.doi.org/10.7554/eLife.19406.003](10.7554/eLife.19406.003)10.7554/eLife.19406.004Figure 1---figure supplement 1.Overview of the clinical and experimental study and role of each partner.This translational study started with a prospective clinical study performed in a clinical investigation center near Paris, France. The objective was to identify healthy subjects with extreme responses to Sotalol 80 mg. Skin punch biopsies were performed in a total of twenty subjects, 10 with low-sensitivity and 10 with high-sensitivity to Sotalol. The fresh skin biopsies were then transferred at the Ectycell company (Romainville, France) in close vicinity of the clinical investigation center. The objective was to culture and bank human dermal fibroblasts and to derive and characterize hiPSC. iPSC clones were then anonymized before any further cardiac experiments were performed. This procedure was agreed by all partners to avoid potential biases in interpreting the recording at the cellular level. iPSCs clones were successfully generated for 17 subjects using retroviral infection and were investigated in this study. For the remaining three subjects (Patients 4, 14 and 20), iPSCs clones were secondarily generated using episomal plasmids and were thus not investigated. The 17 iPSCs clones were then transferred to the Cardiovascular Research Center at Icahn School of Medicine, New York, USA. The objective was to differentiate iPSCs into cardiac myocytes and to perform MEA recordings and drug testing. All required authorizations were obtained.**DOI:** [http://dx.doi.org/10.7554/eLife.19406.004](10.7554/eLife.19406.004)

Twenty subjects with the most extreme responses to sotalol (i.e., 10 subjects with high-sensitivity (high-S) and 10 subjects with low-sensitivity (low-S)) underwent skin biopsy ([Figure 1A and C](#fig1){ref-type="fig"}). These subjects displayed highly contrasted responses to the same pharmacological stimulation (average change in QTcf: 48.5 ± 7.1 ms in high-S subjects vs. 0.2 ± 4.8 ms in low-S subjects; p\<0.0002; [Figure 1C--E](#fig1){ref-type="fig"}) while having no significant differences in their basal ECG characteristics ([Table 1](#tbl1){ref-type="table"}). Demographic characteristics were well balanced between groups with the exception of gender, subjects with high-S being mostly female (90%, n = 9) whereas subjects with low-S were mostly males (80%, n = 8) ([Table 1](#tbl1){ref-type="table"}). Sotalol plasma level was measured 3 hr after sotalol intake and was not significantly different in subjects with high-S as compared to the other participating subjects (753.1 ± 210.9 vs. 620.7 ± 195.3 μg/ml, p=0.10).10.7554/eLife.19406.005Table 1.Related to [Figure 1](#fig1){ref-type="fig"}. Demographic, clinical and electrocardiographic baseline characteristics of subjects with low- vs. high- sensitivity to Sotalol.**DOI:** [http://dx.doi.org/10.7554/eLife.19406.005](10.7554/eLife.19406.005)**Low-sensitivity, n = 10High- sensitivity, n = 10p-value**Age29.9 ± 5.928.3 ± 5.90.53Gender, Male (%)8 (80.0%)1 (10%)0.006Body Mass Index (kg/m²)23.6 ± 0.922.9 ± 2.70.40SBP (mmHg)116.0 ± 8.6113.7 ± 8.30.50DBP (mmHg)72.2 ± 4.868.0 ± 4.20.07Resting heart Rate (bpm)59.6 ± 5.963.2 ± 8.40.37PR interval (ms)166.7 ± 24.7143.5 ± 18.10.09QRS (ms)88.3 ± 5.985.6 ± 7.70.08QTcf (ms)384.7 ± 26.4402.6 ± 20.80.13

Derivation and differentiation of iPSCs into cardiomyocytes {#s2-2}
-----------------------------------------------------------

Dermal fibroblasts were collected from the twenty subjects with high or low-sensitivity to sotalol stimulation. Human iPSCs were derived through retroviral infection of dermal fibroblasts with the reprogramming factors OCT4, SOX2, c-MYC and KLF4 with a successful generation for 17 out of the 20 subjects ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). All iPSC clones expressed the characteristic human embryonic stem cell (ESC) pluripotency markers TRA-1--60, NANOG, OCT3/4 and SSEA-4 ([Figure 2---source data 1](#SD1-data){ref-type="supplementary-material"}), had positive alkaline phosphatase staining. Sixteen iPSC clones had a normal karyotype ([Table 2](#tbl2){ref-type="table"}). One clone presented a significant translocation that was observed in originating fibroblasts. All clones showed silencing of the exogenous retroviral transgenes and reactivation of the endogenous pluripotency genes OCT3/4, NANOG and SOX2 ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).10.7554/eLife.19406.006Table 2.Related to [Figure 2](#fig2){ref-type="fig"}. Fibroblasts and iPS quality control parameters.**DOI:** [http://dx.doi.org/10.7554/eLife.19406.006](10.7554/eLife.19406.006)**IDMycoplasma\*HIV\*, HBV\*, HCV\*, HTLV1 and 2\*Phosphatase alkaline stainingKaryotyping**P11007\~5924\~iPSpolyRoksmANegativeNegativePositive46,XYP11008\~5444\~iPSpolyRoksmBNegativeNegativePositive46, XXP11009\~6426\~iPSpolyRoksmCNegativeNegativePositive46, XYP11013\~5744\~iPSpolyRoksmDNegativeNegativePositive46, XXP11014-5864-iPSpolyRoksmCNegativeNegativePositive46, XXP11015\~6345\~iPSpolyRoksmENegativeNegativePositive46, XXP11018\~5644\~iPSpolyRoksmBNegativeNegativePositive46, XXP11019-6444-iPSpolyRoksmBNegativeNegativePositive46, XYP11020 \~ 7125 \~ iPSpolyRoksmDNegativeNegativePositive46, XYP11021 \~ 6544 \~ iPSpolyRoksmCNegativeNegativePositive46, XXP11023\~5525\~iPSpolyRoksmANegativeNegativePositive46, XXP11024\~5844\~iPSpolyRoksmANegativeNegativePositive46, XXP11026\~6504\~iPSpolyRoksmDNegativeNegativePositive46, XYP11028\~6904\~iPSpolyRoksmJNegativeNegativePositive46, XYP11029-6284-iPSpolyRoksmBNegativeNegativePositive46, XXP11030\~5684\~iPSpolyRoksmANegativeNegativePositive46, XX,t(1;16)^†^P11031\~5204\~iPSpolyRoksmCNegativeNegativePositive46, XY[^2][^3]

The generated iPSCs lines were then encoded to ensure that all further biological experiments were performed in a blinded fashion without knowledge of the associated clinical phenotype ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The code was kept securely by a blinded third party and was only disclosed once all characterizations and electrophysiological measurements with microelectrode array (MEA) mapping system were finalized. All classifications of lines according to the observed response to sotalol were therefore performed before the unblinding process.

Subject-specific iPSCs were differentiated using a small molecule-mediated directed differentiation protocol that involves sequential modulation of the canonical Wnt pathway and yields a high proportion of ventricular-like cardiomyocytes as previously described ([@bib20]). As early as seven days following initiation of cardiac differentiation, spontaneously beating embryoid bodies (EBs) appeared. To test for iPSC-derived cardiomyocytes quality and purity we first performed immunocytostaining studies showing positive staining for the sarcomeric proteins troponin T (cTnT), and alpha-actinin and for the gap-junction protein connexin 43 (Cx43) ([Figure 2A](#fig2){ref-type="fig"}). Cardiac troponin T staining of iPSC-CMs showed a typical striated pattern ([Figure 2A](#fig2){ref-type="fig"}, upper panels). We also determined the cardiomyocytes differentiation efficiency by flow cytometry and found an average of 47.8 ± 19.9% cTNT positive cells. Importantly, after unblinding the study, we did not observe any differences between iPSC lines from the high-S vs. low-S groups (49.2 ± 24.4% vs. 46.7 ± 17.3% respectively, p=0.42). Finally, in line with previous reports ([@bib25]), quantitative PCR demonstrated the presence of major cardiac ion channel genes found in adult left ventricular tissue, including of the relevant *KCNH2* gene ([Figure 2B](#fig2){ref-type="fig"} and [Figure 2---source data 2](#SD2-data){ref-type="supplementary-material"}).10.7554/eLife.19406.007Figure 2.Expression of sarcomeric proteins and ion channels in human iPSC-CMs.(**A**) Confocal microscopy imaging of Troponin T (top), alpha-actinin and connexin 43 (bottom) in single generated iPSC-CMs (from line P11015). Nuclei are stained with DAPI (Blue). (**B**) Gene expression of cardiac ion channel *KCNH2* (encoding hERG) by quantitative PCR; Adult LV tissue is used as a positive control and the level of expression in human ESC-derived cardiomyocytes as a comparator. (**C**) Example of monolayer of iPSC-CMs seeded and attached on a 6-well MEA chip, each well containing nine microelectrodes (black). See also [Video 1](#media1){ref-type="other"}. (**D**) Representative field potential duration (FPD) recorded before and after application of the hERG blocker E4031 (from line P11007). There are five figure supplements.**DOI:** [http://dx.doi.org/10.7554/eLife.19406.007](10.7554/eLife.19406.007)10.7554/eLife.19406.008Figure 2---source data 1.iPSCs characterization.Representative immunostaining for a panel of pluripotent stem cell markers, including Nanog, OCT4, SSEA4 and TRA1-60. Results are reported for each cell line. Typical staining in hESC is reported as a positive control. Scale bar 50 μM.**DOI:** [http://dx.doi.org/10.7554/eLife.19406.008](10.7554/eLife.19406.008)10.7554/eLife.19406.009Figure 2---source data 2.Expression of main human cardiac ion channels.Quantitative PCR results for the expression of 10 major cardiac ion channels including *SCN5A, CACNA1, KCNQ1, KCNE1, KCNJ2, KCNJ11, KChIP2, HCN1, HCN2, HCN4. KCND3* was not detected. Adult LV tissue is used as a positive control and the level of expression in human embryonic stem cells-derived cardiomyocytes as a comparator.**DOI:** [http://dx.doi.org/10.7554/eLife.19406.009](10.7554/eLife.19406.009)10.7554/eLife.19406.010Figure 2---figure supplement 1.Expression of exogenous and endogenous pluripotency genes.Representative gel showing silencing of the four exogenous reprogramming transgenes (OCT3/4; KLF4; SOX2 ; c-MYC) and quantitative PCR results for endogenous pluripotent stem cell genes (OCT3/4; NANOG; SOX2) in the generated hiPSCs.**DOI:** [http://dx.doi.org/10.7554/eLife.19406.010](10.7554/eLife.19406.010)10.7554/eLife.19406.011Figure 2---figure supplement 2.MEA arrays.(**A**) Picture of a 6-well MEA array as used in the study. Each well contains nine micro-electrodes and a limited volume capacity allowing easier contact between cells and micro-electrodes after re-seeding and rapid response to drugs after application in a limited volume of medium. (**B**) Typical micro-electrodes map of the six well array. (**C**) Dose-curve responses to the hERG blocker E4031. Increasing concentrations of E4031 were applied as described in Materials and methods section. Individual data were plotted and a hill equation was fitted allowing estimates of EC50 for each cell lines. Results were obtained in 15 cell lines as two cell lines display no changes in FPD in response to E4031, suggesting expression of a non-functional hERG in these iPSC-CMs. For graphical purposes, cell lines from the low-S group are shown in green and from the high-S group in red.**DOI:** [http://dx.doi.org/10.7554/eLife.19406.011](10.7554/eLife.19406.011)10.7554/eLife.19406.012Figure 2---figure supplement 3.Quality of FPD adjustment.(**A**) Plot of adjusted FPD using the Bazett's formula against the individual inter-beat interval. This plot shows the miss-correction achieved using the Bazett's formula with a significant dependence of FPD to beating rate even after adjustment. (**B**) Plot of adjusted FPD against the individual inter-beat interval after re-estimation of the correction factor to the data set. The plot shows perfect correction with linear regression indicating the lack of influence of the beating rate on the adjusted FPD.**DOI:** [http://dx.doi.org/10.7554/eLife.19406.012](10.7554/eLife.19406.012)

Genetic profiling of cell lines {#s2-3}
-------------------------------

We then screened for common single nucleotide polymorphisms (SNPs, total of 4130) in the 15 genes associated with congenital long QT (*AKAP9, ANK2, CACNA1C, CALM1, CALM2, CAV3, KCNH2, KCNE1, KCNE2, KCNJ2, KCNJ5, KCNQ1, SCN4B, SCN5A, SNTA1)* using a high-density chip (Human Omni 2.5 genotyping array). We found 25 SNPs in *ANK2, SCN5A, KCNQ1, CACNA1C, CALM1, KCNE2, KCNH2* and *KCNJ5* as being significantly imbalanced between low-S vs. high-S groups ([Table 3](#tbl3){ref-type="table"}). This suggests the presence of an allelic series comprising multiple variants of unknown significance that can create a particular predisposing genetic background. Of note, the *CALM1* c.\*1952C (rs3814843) mutated allele was recently associated with increased risk of sudden cardiac death in patients with heart failure ([@bib26]). The allele is rare in Europeans (anticipated allelic frequency of 1.8%) but displayed a 22.2% allelic frequency in the high-S group. In addition, the rare C allele of *KCNH2:*c.307 + 1932G\>C polymorphism (rs3778873) was significantly more frequent in high-S as compared to low-S (minor allelic frequency: 44.4% vs. 6.2% respectively, p=0.02). *KCNH2* encodes for the hERG potassium channel that is targeted by sotalol and this variant was identified in a large genome-wide association study on the physiological regulation of QT interval ([@bib40]).10.7554/eLife.19406.013Table 3.Related to [Figure 2](#fig2){ref-type="fig"}. Single nucleotide polymorphisms in *ANK2, SCN5A, KCNQ1, CACNA1C, CALM1, KCNE2, KCNH2* and *KCNJ5* as being significantly imbalanced (p\<0.05) between low-S vs. high-S groups. Anticipated minor allelic frequency (MAF) was defined using the HapMap-CEU European data. The MAF in cells from the high-S vs. low-S groups was determined once the study was unblinded. Fisher's exact test was used to compare observed MAFs in high-S vs. low-S groups.**DOI:** [http://dx.doi.org/10.7554/eLife.19406.013](10.7554/eLife.19406.013)**GeneRs numberAnticipated MAFObserved MAF Low-SObserved MAF High-Sp value**ANK2rs170459356.8%0%22.2%0.03rs6231490140%56.25%27.8%0.037rs1767625610.2%12.5%38.9%0.03rs96709938.1%25%44.4%0.027rs483432146.9%37.5%55.6%0.02rs3530837048.3%25%66.7%0.025rs93183842.5%31.25%66.7%0.048SCN5Ars737512319.2%43.75%11.2%0.007rs124919877.6%0%22.2%0.03rs987138534.1%6.25%33.3%0.02rs981814819.2%56.25%16.7%0.049KCNQ1rs425552015.5%18.75%0%0.043rs15128832.7%0%22.2%0.031rs718579rs1102299639.8% 41.2%12.5%27.8%0.034rs15121240.8%50%33.3%0.05CACNA1Crs379429912.4%18.75%0%0.043rs4765661rs223801815.8% 17.3%31.25%5.6%0.027CALM1rs38148431.8%0%22.2%0.031rs23005027.5%6.25%33.3%0.023KCNE2rs2840936830.8%18.75%38.9%0.0239KCNH2rs207241137.5%18.75%44.4%0.027rs377887315.8%6.2%44.4%0.02KCNJ5rs792441624.6%0%27.8%0.013

The library of iPSC-CMs reproduces susceptibility to develop cardiotoxic drug response {#s2-4}
--------------------------------------------------------------------------------------

To evaluate the electrophysiological properties of iPSC-CMs, we used a microelectrode array (MEA) mapping system ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). iPSC-CMs were seeded onto a 6-well MEA chamber in order to form a monolayer in contact with the electrodes. Few days after seeding iPSC-CMs regain spontaneous beating activity thus allowing recordings of field potential duration (FPD) ([Figure 2C--D](#fig2){ref-type="fig"} and [Video 1](#media1){ref-type="other"}). FPD is analogous to the QT interval in the electrocardiogram (ECG) and was previously shown to correlate with action potential duration (APD) and can be used to test drug effects on repolarization ([@bib35]). IPSC-CMs were first tested for their responses to E4031, a specific and potent experimental hERG blocker. E4031 resulted in a dose-dependent increase in FPD with typical flattening of the waveform in all but two cell lines ([Figure 2D](#fig2){ref-type="fig"} and [Figure 2---figure supplements 2](#fig2s2){ref-type="fig"} and [3](#fig2s3){ref-type="fig"}). There was moderate inter-line variability, except for line P11019 which demonstrated higher sensitivity to E-4031 and was found to belong to the high-S group after unblinding. There was however no significant differences in sensitivity to E4031 between groups as assessed by computations of half maximal effective concentration EC50 (2.4 ± 0.7 × 10^−8^ vs 6.6 ± 3.0 × 10^−8^ M in high-S and low-S groups respectively, p=0.59) or of maximal effect Emax (49 ± 20% vs 30 ± 2% in high-S and low-S groups respectively, p=0.76). Two lines displayed no responses to E4031 and were found as having the lowest expression of hERG (P11021 and P11023, [Figure 2B](#fig2){ref-type="fig"}). Because of the lack of response to a pure hERG blocker and of appropriate recordings to detect effects of QT prolonging drugs with the MEA system, sotalol response was not further tested on these two lines.Video 1.Spontaneous beating activity of monolayer iPSC-CMs seeded onto one well of a 6-well MEA chamber.**DOI:** [http://dx.doi.org/10.7554/eLife.19406.014](10.7554/eLife.19406.014)10.7554/eLife.19406.014

The response to the clinically relevant drug sotalol was then tested in a blinded fashion in the remaining lines. For quality purposes, results from the iPSC line presenting a significant translocation were excluded from further analyses. However, the inclusion of the results obtained with this iPSC line did not change the statistical significance of the results. Final analyses were thus performed on a total of 14 lines (7 vs. 7 lines in low-S and high-S groups respectively).

After unblinding, we found that the different recordings showed a significantly higher response to sotalol in the CMs generated from iPSCs derived from high-S subjects as compared to low-S subjects ([Figure 3A--D](#fig3){ref-type="fig"}). Increasing sotalol concentrations was associated with a significant prolongation in FPDs in all iPSC-CMs, an effect that was however significantly enhanced in lines from the high-S group ([Figure 3A](#fig3){ref-type="fig"}). There was a dose-dependent sotalol-induced FPD prolongation that typically appears for sotalol concentrations above 30 μmol/L ([Figure 3A](#fig3){ref-type="fig"}), as seen in other reports ([@bib35]). Of note, the application of low sotalol concentration (10 μmol/L), a concentration this is closer to typical sotalol plasma levels, was already associated with a significant increase in FPD in lines from the high-S group as compared to low-S (p=0.03). The maximal FPD prolongation observed in response to sotalol was also significantly higher in the high-S as compared to low-S iPSC-CMs (52 ± 6% vs. 27 ± 6%, p=0.02, [Figure 3B](#fig3){ref-type="fig"}). Sotalol is known to induce arrhythmic events including ectopic beats and short-long-short rhythm. We found that 5 of the seven lines derived from the high-S group displayed arrhythmias in response to sotalol stimulation as they showed development of irregular spontaneous beating rate. On the other hand, arrhythmias only occurred in one of the eight lines from the low-S group ([Figure 3C](#fig3){ref-type="fig"}). We plotted the relative change in FPD in response to sotalol 30 μM against the observed change in QTcf in donors ([Figure 3D](#fig3){ref-type="fig"}). With the exception of one cell line in each group, the remaining six low-S and six high-S cell lines were correctly discriminated according to the clinical phenotype. These data indicate that the contrasted responses to sotalol in iPSC-derived CMs are strongly related to the inter-individual differences in response to sotalol as recorded during clinical investigations.10.7554/eLife.19406.015Figure 3.Differences in iPSC-CMs responses to Sotalol stimulation according to clinical sensitivity to Sotalol.(**A**) Adjusted FPD (aFPD) measured in iPSC-CMs derived from subjects with low-sensitivity (green) vs. high-sensitivity (red) in response to increasing concentrations of sotalol. aFPD are normalized to baseline values to account for inter-lines variability in aFPD values. Two-way analysis of variance demonstrates a significant influence of sotalol concentrations (p\<0.0005) and of the sensitivity group (p\<0.02). \*p\<0.05 for post-hoc comparison between groups; high-S vs. low-S. N = 2--5 recordings per cell lines per concentrations. (**B**) Maximal change in aFPD observed during sotalol stimulation. (**C**) Proportion of observed arrhythmias after sotalol application. (**D**) Data plot graph showing the correlation between aFPD observed in iPSC-CMs and the DeltaQTcf observed in donors. The aFPD data are reported for sotalol 30 μM concentration. Data points are clustered in two distinct groups. Except for two lines (one line in each group), a threshold a 25% in aFPD change (dashed line) correctly discriminates cells from both groups.**DOI:** [http://dx.doi.org/10.7554/eLife.19406.015](10.7554/eLife.19406.015)

We also evaluated the effect of sotalol on action potential duration (APD) measured in a representative iPSC-CMs line from each group (P11009 as low-S and P11029 as high-S). Experimenter for APD measurement was however kept blinded of the observed drug sensitivity of selected iPS lines. Sotalol (100 and 300 µM) significantly prolonged the action potential, the duration of 90% repolarization (APD~90~) of high-S (P11029) iPSC-CMs (289 ± 22 in drug-free vs. 492 ± 66 and 435 ± 92 after 100 and 300 µM sotalol, respectively n = 5) but not that of the low-S line (P11009) even at high dose (339 ± 63 vs. 450 ± 77 ms after 300 µM sotalol, n = 5) ([Figure 4A--B](#fig4){ref-type="fig"} and [Table 4](#tbl4){ref-type="table"}).10.7554/eLife.19406.016Figure 4.Patch-clamp analysis of action potential (AP) in representative iPSC-CMs.(**A**) Representative AP tracings of the iPSC-CMs generated from the low-S (P11009) and high-S (P11029) lines in control and sotalol-treated conditions. (**B**) bar chart summarizing the APD~90~ in control and sotalol-treated conditions for the hiPSC-CMs generated from both low-S (P11009) and high-S (P11029) hiPSC cell lines (n = 5 for each condition). \*p\<0.05; \*\*p\<0.01, ANOVA, followed by Tukey\'s, sotalol-treated versus respective control without sotalol application.**DOI:** [http://dx.doi.org/10.7554/eLife.19406.016](10.7554/eLife.19406.016)10.7554/eLife.19406.017Table 4.Related to [Figure 4](#fig4){ref-type="fig"}. AP parameters of low-S and high-S iPSC-derived cardiomyocytes at baseline control condition. AP data are mean ± SE. APD50/APD90, AP duration measured at 50% or 90% repolarization; MDP, maximum diastolic potential. None of the baseline AP parameters was significantly different between the two cell lines.**DOI:** [http://dx.doi.org/10.7554/eLife.19406.017](10.7554/eLife.19406.017)Low-S (11009) (n=7)High-S (11029) (n=5)Firing Frequency (mV)1.26 ± 0.291.03 ± 0.28Amplitude (mV)88.3 ± 3.685.1 ± 4.7Upstroke velocity (mV/ms)11.7 ± 1.014.0 ± 2.0Decay velocity (mV/ms)−7.2 ± 1.4−11.1 ± 3.5APD50 (ms)306.4 ± 57.9299.4 ± 22.0APD90 (ms)341.8 ± 58.6338.4 ± 21.4MDP (mV)−69.4 ± 3.2−68.0 ± 1.3

Dysregulation of downstream regulators of cardiac ion channels {#s2-5}
--------------------------------------------------------------

To gain insight into molecular mechanisms leading to differential susceptibility to developing diLQT, we performed a transcriptomic profiling of iPSC-CMs from high-S vs. low-S groups using RNA-sequencing. We looked for differentially expressed genes (DEGs) between the two groups (all cell lines included) and used a prior knowledge based approach to identify potential risk markers that could be mechanistically connected to QT prolongation development. By analyzing the LQTS neighborhood in the human interactome we recently demonstrated that graph theoretical models allow the prediction of new gene variants and drug targets that are involved in disease pathogenesis ([@bib2]). Here, we used a similar approach and searched for differentially expressed direct neighbors of the known congenital LQTS genes in the human interactome ([Figure 5A](#fig5){ref-type="fig"}). Of note, expression of these LQTS genes was similar between high-S and low-S groups. We identified four up-regulated (*DLG2, KCNE4, PTRF,* and *HTR2C*) and one down-regulated direct neighbors (*CAMKV*) ([Figure 5A--B](#fig5){ref-type="fig"}). Among these newly identified candidates, *DLG2* (a member of the family of anchoring proteins called MAGUK), *KCNE4* (a regulatory sub-unit of potassium channel), *CAMKV* (a kinase-like protein that, in the presence of calcium, interacts with calmodulin (*CALM1*), and *PTRF* (Polymerase I and transcript release factor, or cavin-1) were relevant candidates as downstream regulators of cardiac ion channels.10.7554/eLife.19406.018Figure 5.Identification of dysregulated genes as direct neighbors of QT-associated network in high-S iPSC-CMs.(**A**) Known LQTS genes were used as seed nodes (green squares) in the human interactome and five differentially expressed direct neighbors were identified (circles) (path length 1). Up-regulated genes are colored orange, down-regulated genes are in blue. (**B**) Relative expression of identified genes in each group. Males are represented in blue and females in red. Individual samples are represented by the same symbols in all diagrams. (**C**) Comparison of the log2-fold changes between the high-S and the low-S groups with the normalized counts of how often a gene (blue or orange dots) was found to be up- or down-regulated between the male and female groups. As there are more females in the high-S group and more males in the low-S groups, report of genes in the lower left or upper right quadrants indicate a gender-specific effect while the lower right and upper left quadrants argue for the lack of gender-specific effect. Except for *HTR2C*, dysregulation of all other candidate genes was suspected to occur independently of gender. There is one figure supplement.**DOI:** [http://dx.doi.org/10.7554/eLife.19406.018](10.7554/eLife.19406.018)10.7554/eLife.19406.019Figure 5---figure supplement 1.Prediction of sex hormones-related transcription factors.Predicted regulatory transcription factors of the identified DEGs (*DLG2, KCNE4, CAMKV, PTRF, HTR2C)* based on two transcription factor target databases (Chea background and Transfac) and ranked by significance. The sex-hormone related transcription factors (in orange) were ranked 16 (AR), 20 (ESR1) and 24 (ESR2) or 27 (PGR) and 180 (ESR1) while the top 10 candidates were independent of sex hormones influence (in blue).**DOI:** [http://dx.doi.org/10.7554/eLife.19406.019](10.7554/eLife.19406.019)

The expression levels of the genes between the low-S and the high-S groups show that the risk specific expression (i.e. low expression for *CAMKV* and high expression for the other direct neighbors) does not accumulate on a few high-S subjects but is more or less equally distributed over all high-S subjects ([Figure 5B](#fig5){ref-type="fig"}). Each subject has a risk-associated expression of at least one direct neighbor, arguing for multiple ways to disturb the LQTS genes and therefore confer different susceptibility to develop diLQT.

Since most of the high-sensitivity subjects were females, while most of the low sensitivity subjects were males, we then estimated whether gender could impact our results. To neutralize gender-specific effects on gene expression, we generated new groups consisting of one high-S and one low-S subject of the same gender (16 female groups, six male groups, [Table 5](#tbl5){ref-type="table"}). DEGs were identified between all possible combinations of one female versus one male group (16 × 6 = 96 sets of DEGs). We counted for each gene how many sets of DEGs identified the gene as significantly up-regulated or down-regulated. Down-regulated counts were subtracted from up-regulated counts and resulting netto counts were normalized to the number of total comparisons (i.e. divided by 96). Using this approach, a gene that is up-regulated in the high-S group because of gender specific expression, should be identified as significantly up-regulated in most of the female versus male groups sets of DEGs. The same accounts for down-regulated genes. As shown in [Figure 5B and C](#fig5){ref-type="fig"}, this trend was not observed for most of the genes, arguing against gender differences being the reason for differential gene expression between the high-S and low-S group.10.7554/eLife.19406.020Table 5.Related to [Figure 5](#fig5){ref-type="fig"}. Generation of new groups associating one high-S and one low-S line of the same gender (six groups for males and 16 groups for females) in order to neutralize gender-specific effects on gene expression. These groups were then used to determine DEGs between the high-S and low-S groups independent of gender.**DOI:** [http://dx.doi.org/10.7554/eLife.19406.020](10.7554/eLife.19406.020)**Male groupsFemale groups**P11019 (high) + P11028 (low)P11008 (high) + P11030 (low)P11019 (high) + P11026 (low)P11015 (high) + P11030 (low)P11019 (high) + P11020 (low)P11013 (high) + P11030 (low)P11019 (high) + P11009 (low)P11029 (high) + P11030 (low)P11019 (high) + P11031 (low)P11018 (high) + P11030 (low)P11019 (high) + P11007 (low)P11024 (high) + P11030 (low)P11023 (high) + P11030 (low)P11021 (high) + P11030 (low)P11008 (high) + P11014 (low)P11015 (high) + P11014 (low)P11013 (high) + P11014 (low)P11029 (high) + P11014 (low)P11018 (high) + P11014 (low)P11024 (high) + P11014 (low)P11023 (high) + P11014 (low)P11021 (high) + P11014 (low)

Finally, to further investigate if the DEGs are the consequence of sex specific gene expression, we predicted regulatory transcription factors of the DEGs based on two transcription factor target databases and ranked them by significance ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). The sex-hormone related transcription factors were ranked 16 (AR), 20 (ESR1) and 24 (ESR2) or 27 (PGR) and 180 (ESR1), and no sex hormone related transcription factor was among the top 10 candidates. These data suggest that the observed differences in expression patterns between high-S and low-S iPS-CMs are mostly indicative of a signature associated with drug sensitivity rather than a gender effect.

Discussion {#s3}
==========

Our data illustrate the potential of using a genetically diverse panel of subject-specific iPSCs to model complex and acquired phenotypes. So far, iPSCs technology has been successful in recapitulating monogenic diseases with clear causative mutations including congenital long QT syndrome ([@bib17]; [@bib32]; [@bib50]). In contrast, diLQT develop in clinically normal individuals who have a genetic predisposition requiring an additional stressor to become manifest ([@bib42], [@bib44]). The exact nature of this predisposing genetic background remains uncertain ([@bib39]) but is likely made of an allelic series of common variants with modest independent effect on cardiac repolarization but potential for a stronger impact in a polygenic model, as exemplified by our genetic profiling.

Here, we provide evidence that susceptibility to develop diLQT can be best reproduced in vitro using a targeted library of iPSCs derived from patients presenting with an extreme pharmacodynamic response to drug stimulation in vivo. Extreme phenotype selection is a well-defined methodology that helps enrich the frequency of alleles that contribute to a trait and this methodology has been successfully applied in genetic studies aimed at identifying variants associated with complex traits ([@bib8]). The use of this methodology is particularly suitable when investigating variability in drug responses by segregating individuals with opposite predisposing genetic makeup, a characteristic that can be transmitted to iPSCs as shown by our data. Importantly, in order to avoid experimental biases, in vitro assessment of iPSC-CMs sensitivity to sotalol was performed blinded to the clinical phenotype. In addition, as we aimed at reproducing a more complex phenotype, we designed our study with a larger sample size than typical studies using iPSCs for disease modeling of monogenic disorders. As a consequence, we were only able to explore one iPSC clone per patient and we did not evaluate potential inter-line variability. The likelihood that inter-line variability would have systematically biased our results to reproduce the anticipated effect as seen in vivo and thus explain our results is however unlikely on a panel of 17 different cell lines as appreciated by low p-values for comparison between groups ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}). Under our hypothesis, it is likely that the discrepant results obtained in two cell lines reflect that potential false results associated with inter-line variability from a same patient. However, external replication would further strengthen the potential of subject-specific iPSCs to model complex phenotypes as shown in our seminal study.

This library also represents a unique opportunity to explore the molecular mechanisms underlying pro-arrhythmic adverse drug reactions. The transcriptomic comparison of the generated iPSC-CMs from both groups combined with bioinformatics network analysis revealed significant changes in expression of genes related to the regulation of ion channels homeostasis (*DLG2, KCNE4, CAMKV* and *PTRF*). Of note, while none of these genes have been previously associated with the occurrence of diLQT, *CAMKV* is coding for a kinase-like protein that, in the presence of calcium, interacts with calmodulin (*CALM1*), a critical regulator of ion channels involved in congenital long QT syndrome 14 ([@bib9]) and in loperamide-induced long QT ([@bib2]). Additionally, mutations in *PTRF* (Polymerase I and transcript release factor, or cavin-1) cause a particular form of congenital generalized lipodystrophy (type 4, CGL4) that is associated with features of long QT syndrome and high rate of sudden cardiac death ([@bib41]). *PTRF* is involved in the formation of caveolae ([@bib34]), that are critical in cardiac ion channels trafficking to the plasma membrane ([@bib28]). In addition to the involvement of *DLG2* and *KCNE4* genes in the direct regulation of scaffolding, trafficking and gating kinetics of some cardiac potassium channels ([@bib23]; [@bib24]), our study suggest for the first time that diLQT might be related to changes in downstream regulation of the cardiac repolarization machinery. Further experiments will be required to understand the exact contribution of each of these candidates and whether they might act in combination to confer susceptibility to develop diLQT. Similarly, future studies using single-cell RNA sequencing on cardiomyocytes derived from our library of subject-specific iPSCs would be needed to better identify and characterize differentially expressed genes and pathways. Lastly, we identified an up-regulation in *HTR2C* (5-hydroxytryptamine receptor 2C), a G-protein coupled receptor for serotonin that is expressed in the heart. Upon activation HTR2C activates down-stream signaling cascades to promote the release of Ca2+ from internal stores. Interestingly, serotonin receptor agonists have been associated with higher risk for diLQT ([@bib21]; [@bib47]). Intriguingly, we found non-significant trends for differences between groups in response to E-4031, a selective hERG channel blocker. Sotalol primarily prolongs cardiac repolarization through hERG inhibition but also have a non-selective competitive β-adrenergic receptor blocker activity and can thus affect other cardiac repolarization components that are associated with higher susceptibility to develop diLQT. Whether sotalol has a direct or indirect effect on the candidates identified in this study would deserve further investigations.

Many studies have reported a higher susceptibility to diLQT in premenopausal women as compared to men including in response to sotalol ([@bib10]; [@bib29]), an observation that is in line with the results of our prospective clinical investigation. It has been suggested that sex hormones can influence cardiac repolarization by modulating expression and function of cardiac ion channels but their effect is complex to appreciate as levels fluctuate with time and age and the different sex hormones can have counterbalancing effects ([@bib15]; [@bib37]). Here, we were able to reproduce susceptibility to develop diLQT in vitro in a hormone-free environment. We performed specific analyses that did not support an important role of gender to explain our results, including the lack of a gender-specific gene expression signature and the lack of significant sex hormone-related transcription factors. Importantly, our data suggest that the identified genes should work as predisposing genes in both genders thus arguing for the existence of an intrinsic predisposing background that is carried by iPS cells but do not depend on gender. Of note, it has recently been shown that women have in mean a greater intrinsic sensitivity to sotalol as compared to men, an effect that however remains widely variable at the individual level ([@bib10]).

The development of a new generation of human-based screening assays for testing individual drug reactions ([@bib16]; [@bib30]) could help in better predicting adverse drug effect that usually develop in a relatively low proportion of susceptible individuals in the general patient population ([@bib3]). Interestingly, we were able to detect significant differences in response to the lowest sotalol concentrations (i.e., 10 µM) in iPSC-derived cardiomyocytes from subjects clinically presenting with high sensitivity to sotalol. This suggests that the iPSC-derived platform could efficiently detect individual differences in the range of concentrations that is near the typical sotalol plasma levels. Finally, further developments in differentiation protocols ([@bib4]), in functional maturation of iPSC-derived cells ([@bib27]) or in iPSC-based bioengineering ([@bib48]; [@bib55]) might also improve the overall predictability of the method.

Our data illustrate the potential of iPSCs technology for the prediction of individual risk and for its use in precision medicine. We found a limited number of lines with discrepant results in vitro as compared to the clinical phenotype, suggesting a good accuracy of the approach. However, as we only investigated patients with extreme responses to sotalol, our study was not designed to accurately assess the predictive value of the test. This should be adequately addressed in larger prospective studies.

In conclusion, this study underscores the power of developing a panel of iPSCs to model complex traits such as susceptibility to develop cardiotoxic drug response.

Material and methods {#s4}
====================

Subjects and clinical investigations {#s4-1}
------------------------------------

To participate to the study, male or female volunteers had to fulfill the following inclusion criteria: aged 18 to 40 years, body mass index from 19 to 29 kg/m^2^, no previous history of cardiac disease, no major disorders, no medications known to affect cardiac repolarization (as defined by <https://www.crediblemeds.org/everyone/composite-list-all-qtdrugs>). All volunteers had normal laboratory evaluations and a normal clinical examination with a resting heart rate ≥50 beats min^−1^ and a systolic blood pressure ≥100 mmHg. Cardiac conduction and repolarization was assessed on a 12-lead resting electrocardiogram and participants were excluded in case of atrio-ventricular conduction disorder (PR interval \>200 ms), QRS \>100 ms and in case of prolonged QTcF \>450 ms. Other exclusion criteria were familial or personal history of sudden death or unexplained syncope, concomitant use of illicit drugs, asthma.

The protocol was approved by the local institutional ethics committee and all subjects gave their written informed consent for participation to the study.

All investigations were performed prospectively at a single clinical center (Biotrial Paris, Rueil Malmaison, France). In a first phase, eligible subjects were admitted at 7:30am at the clinical investigation center after an overnight fast. Subjects were placed in a quiet room and rested for 30 min in the supine position. Cardiac rhythm and non-invasive blood pressure monitoring were started. The quality of ECG recordings was assessed and baseline recordings were performed during the 5 min preceding sotalol oral administration (80 mg tablet). ECG recordings were then performed 3 hr after sotalol intake, i.e. around peak plasma concentration. Blood samples for the determination of sotalol concentration were obtained at baseline and 3 hr after sotalol administration. Volunteers were allowed to leave the clinical investigation center 5 hr after sotalol intake after cardiac repolarization had normalized.

In a second phase (7 to 35 days after phase 1), 20 subjects with the most extreme responses to sotalol (10 with smallest QTcF changes and 10 with the largest QTcF changes from baseline in response to sotalol) were asked to come to the clinical investigation center and had a skin biopsy under local anesthesia using a sterile 3 mm skin punch.

ECG recording and analysis {#s4-2}
--------------------------

Before and 3 hr following sotalol administration, 30 s digital 12-lead electrocardiograms were recorded using a Cardioplug device (Cardionics Inc, Brussels, Belgium) connected to a personal computer. All electrocardiogram recordings were then read by the same investigator, blindly of drug administration. The same chest lead with the largest T-wave amplitude was selected for QT interval measurements in a given subject. QT interval was measured manually directly on the computer screen by changing position of cursors indicating the start and the end of the cardiac interval: RR (interval between two successive R waves) and QT (tangent method). Baseline QTc was assessed as the mean of three electrocardiographic recordings obtained within 5 min before drug administration. QT was corrected by the Fridericia cubic root formula (QTcf), which minimizes the errors due to the square root Bazett formula. The clinical phenotype was defined by modifications in QTcf duration (ms) 3 hr after sotalol intake.

Human iPSCs derivation {#s4-3}
----------------------

Fibroblast derivation was performed immediately after biopsy arrival at Ectycell / Cellectis Stem Cell Company (Evry, France). Skin biopsy of a 3 mm diameter punch was cut into about 20 small explants with scalpels and placed in 6-well plates and cultured with fibroblast growth medium containing DMEM medium (Gibco), 10% of FBS (PAA Laboratories), 10 ng/ml FGF-2 (Invitrogen, Carlsbad, CA) and 1% penicillin-streptomycin (Gibco). Cells were fed every 2--3 days. In this culture, fibroblasts appeared and became confluent on average 33 days after plating. The fibroblasts were then subcultured using 0.25% trypsin (Invitrogen) then re-suspended and cultured into T75 flasks using fibroblast growth medium without antibiotics. An average of 62 million fibroblasts per biopsy was obtained in 4--7 weeks at passage 1. The fibroblasts were tested for mycoplasma contamination and no contamination was detected (MycoAlert TM Mycoplasma Detection kit, Lonza France).

Reprogramming of fibroblasts derived from patient's skin biopsies into iPSCs was carried out using polycistronic retroviral vectors. The fibroblasts were seeded in 6-well plates at a defined cell density (100,000 cells/well) and cultured with fibroblast growth medium (DMEM medium containing 10% of FBS and 10 ng/ml FGF-2). For transduction, cells were incubated with polycistronic retroviral vectors (provided by Vectalys, Toulouse, France) carrying human Oct4, Sox2, Klf4, and c-Myc (OSKM) expression factors in fibroblast medium supplemented with 6 µg/ml polybrene (Sigma, St Louis, MO) overnight. The cells were transduced at a multiplicity of infection of 5. Four days post-infection, the cells were split by using 0.25% trypsin and plated at 100,000 cell/well in 0.1% gelatin-coated 6-well plates in fibroblast growth medium. After 24 hr, the medium was switched to the human pluripotent stem cell medium (DMEM/F12, 20% knockout serum replacement, 1× non-essential amino acid, 2 mM L-glutamine, 0.1 mM 2-mercaptoethanol, 20 ng/ml FGF-2 and 1% penicillin-streptomycin) with 0.5 mM Valproic acid (VPA). The media were changed every day. Around 20--25 days post-infection, the human ESC-like colonies appeared. The iPSCs colonies were picked and expanded in mTeSR1 (Stemcell technologies, Canada) on matrigel matrix (BD Biosciences France) coated plates. The iPSCs were passaged with Accutase (10 ml pre 75 cm2 surface area, Millipore, Billerica, MA) and the culture medium was changed daily.

Colonies fulfilling established 'stemness' criteria were selected and sent to the Cardiovascular Research Center at Mount Sinai School of Medicine, New York, USA for differentiation toward the cardiomyocyte lineage and pharmacological characterization.

Differentiation of iPSCs into cardiomyocytes {#s4-4}
--------------------------------------------

The iPSCs were differentiated into cardiomyocytes using a directed differentiation method. Cardiomyocytes differentiation was initiated in suspension cultures on ultra-low attachment dishes (Corning, France) in mTESR1 medium supplemented with BMP4 10 ng ml-1) and Blebbistatin (5 μM) for 24 hr. The medium was then replaced with the basal differentiation medium (StemPro34, 50 μg ml-1 ascorbic acid, 2 mM GlutaMAX-I) supplemented with BMP4 (10 ng ml-1) and Activin-A (25 ng ml-1) for 48 hr (days 1--3) and then switched to basal differentiation medium for another 36 hr (days 3--4.5). Finally, the cells were differentiated in basal differentiation medium supplemented with IWR-1 (2.5 μM) for 96 hr (Day 4.5--8.5). The differentiated cardiomyocytes were maintained in basal differentiation media for up to four weeks. All cytokines were purchased from R and D. The small molecules were purchased from Sigma. All differentiation cultures were maintained in 5% CO2/air environment.

Immunocytochemistry {#s4-5}
-------------------

iPSCs were cultured on matrigel-coated coverslips, fixed in paraformaldehyde and permeabilized in blocking/permeabilization buffer (2% BSA/2% FBS/0.05% NP-40 in PBS) for 45 min and incubated with primary antibodies overnight at 4°C. Then the cells were washed in PBS and incubated with Alexa-conjugated secondary antibodies (Invitrogen) diluted in blocking/permeabilization buffer (1:750). Finally, after washing in PBS the cells were counterstained with DAPI. Immunofluorescence images were acquired using an Olympus X41 microscope. The following antibodies were used: mouse monoclonal anti-OCT4 (Santa Cruz biotechnology, Germany), goat polyclonal anti-NANOG (R and D systems), mouse monoclonal anti-SOX2 (R and D systems), mouse monoclonal anti-SSEA-4 (R and D systems, Minneapolis, MN), mouse monoclonal anti-TRA-1--60 (R and D systems). Similarly, iPSC-derived cardiomyocytes were dissociated and cultured on matrigel-coated coverslips for 4--5 days, fixed in paraformaldehyde and permeabilized in blocking/permeabilization buffer for 45 min. The following primary antibodies were used: mouse monoclonal anti-cardiac troponin T (Thermo Fisher Scientific, France), mouse monoclonal anti-connexin 43, and mouse monoclonal anti-α-actinin. Confocal imaging was performed using a Leica SP5 confocal system.

Flow cytometry {#s4-6}
--------------

Single-cell suspensions were obtained by dissociating EBs with 0.025% trypsin for 15 min at 37°C. The cells were then fixed with 4% paraformaldehyde for 15 min and washed twice with phosphate buffered saline (PBS). The fixed cells were first permeabilized in permeabilization buffer (0.2% Triton X-100 in PBS) for 30 min and then blocked with 10% goat serum for 25 min. Cells were then incubated with the primary antibody (anti-cardiac troponin T; Thermo Fisher Scientific). After 1 hr, the cells were washed in PBS, incubated with Goat anti-mouse IgG1 - Alexa 488 secondary antibody for 45 min, and finally washed twice with PBS. All procedures were performed at 4°C. Fluorescence-activated cell sorting analysis was carried out using a BD LSR analyzer (BD Biosciences).

Quantitative PCR {#s4-7}
----------------

Relative gene expression was determined using a two-steps quantitative real-time PCR method. Total RNA was isolated with the RNeasy Isolation kit with on-column DNase I treatment (Qiagen, Germany) and reverse-transcribed using the cDNA Synthesis Kit (Biorad, Hercules, CA). Quantitative RT-PCR was performed with the Quanta SYBR Green Supermix (Quanta biosciences, Beverly, MA) on the ABI Prism 7500 Real Time PCR System (Applied Biosystems, Foster City, CA). Fold changes in gene expression were determined using the comparative CT method (△△Ct) with normalization to the housekeeping gene B2M.

SNPs genotyping array {#s4-8}
---------------------

Single nucleotide polymorphism (SNP) genotyping analysis was performed using the Illumina HumanOmni2.5--8 beadchip genotyping array, which comprise a comprehensive set of around 2.6 million SNPs (with MAF \>2.5%) across the genome. The list of mapped SNPs can be found at <http://support.illumina.com/downloads/infinium-omni2-5-8-v1-3-support-files.html.> All genomic DNA was isolated from iPSC clones using Quick-gDNA Mini Prep kit (Zymo Research, Irvine, CA). Input genomic DNA (200 ng) was processed, hybridized to the array and scanned on an Illumina HiScan at the Mount Sinai Genomic Core Facility. Based on chromosome coordinates, we extracted SNPs in *AKAP9, ANK2, CACNA1C, CALM1, CALM2, CAV3, KCNH2, KCNE1, KCNE2, KCNJ2, KCNJ5, KCNQ1, SCN4B, SCN5A, SNTA1* using Genome Studio (Illumina, San Diego, CA). Genotypes were estimated and compared between low-S and high-S groups. We used HapMap-CEU data to estimate the anticipated minor allelic frequency in European population.

RNA-Sequencing {#s4-9}
--------------

Total RNA was extracted using Zymo columns and 2 µg were used to generate a RNA-seq sequencing library. Poly-A selection and mRNA-SEQ library preparation were performed at the Mount Sinai Genomics Core Facility. Sequencing (50 bases, paired ends) was performed using an Illumina HiSeq2500. Annotated reads were obtained using STAR and HTSeq and normalized to full library size.

Sequencing reads were aligned to the human reference genome \'hg19\' using Tophat 2.0.8 ([@bib53]), samtools-0.1.7 and bowtie 2.1.0 ([@bib22]) and differentially expressed genes were identified with cufflinks 1.3.0 ([@bib54]).

The total number of sequenced reads in a sample influences the likelihood to detect a lowly to moderately expressed gene, especially in case of lower read counts ([@bib31]). In consequence, it could happen that fewer genes are detected in a sample with a lower read count than in a sample with a higher read count. Such an experimental artifact might distort normalization including total reads as well as upper quartile normalization, the two normalization options that are offered by cufflinks. Both normalization approaches only change the number of reads that are associated with a gene, but not the number of identified genes. Consequently, the same number of normalized reads might be distributed over a different number of genes in two different samples, causing the detection of an equally expressed gene in both samples as differentially expressed. To prevent such an experimental artifact we randomly removed reads from the sequenced samples until every sample had the same number of read counts. Reads were aligned to the human reference genome hg19 with Tophat using the ensemble GTF file as a gene annotation reference and the option \'no-novel-juncs\'. Output BAM files were directly subjected to Cufflinks to identify differentially expressed genes, using the options \'multi-read-correct\', \'upper-quartile-norm\' and \'frag-bias-correct\' against the hg19 genome. Differentially expressed genes were identified based on a FDR of 5% and a minimum fold change (log~2~((FPKM~condition1~+1)/(FPKM~condition2~ + 1)) \>= ± log~2~(1.3)).

We determined differentially expressed genes between the high-S (P11008, P11013, P11015, P11018, P11019, P11021, P11023, P11024, P11029) and the low-S (P11007, P11009, P11014, P11020, P11026, P11028, P11030, P11031) cell lines. To compare gene expression values of the identified candidates across individual samples, we subjected all samples as individual conditions to the cufflinks analysis pipeline in the same way as described above. We used the FPKM values of the cufflinks results file as a measure for normalized gene expression.

To analyze, if differentially expressed genes between the high-S and low-S group are caused by gender differences between the two groups, we generated all possible combinations of one high-S female and one low-S female (16 groups) and one high-S male and one low-S male (six groups). We determined differentially expressed genes between all possible combinations of one female group versus one male group (16 × 6 sets of DEGs). For each gene we counted in how many sets of DEGs it was detected as significantly up-regulated or down-regulated, subtracted the counts for down-regulated detections from the counts for up-regulated detections and divided the resulting number by the counts for sets of DEGs (i.e. by 96).

Network analysis and direct neighbors identification {#s4-10}
----------------------------------------------------

To search for differentially expressed direct neighbors of LQTS disease genes, we generate a human interactome by merging all protein-protein interaction databases of the Expression2 kinases suite ([@bib7]), except the \'Predicted PPI\' database, and a recently published protein-protein interaction network ([@bib45]). Small letter symbols of the merged interactome were replaced by their human homologues, using the Mouse Genome Informatics mouse-human orthology database and the NCBI mouse-human homologene database. Finally, we removed all network nodes that were not official human gene symbols as reported in the NCBI geneInfo database. Differentially expressed genes in the direct neighborhood of LQTS disease genes (\'AKAP9\', \'ANK2\', \'CACNA1C\', \'CALM1\', \'CALM2\', \'CAV3\', \'KCNE1\', \'KCNE2\', \'KCNH2\', \'KCNJ2\', \'KCNJ5\', \'KCNQ1\', \'SCN4B\', \'SCN5A\', \'SNTA1\') were identified (path length = 1).

Prediction of upstream regulatory transcription factors {#s4-11}
-------------------------------------------------------

All differentially expressed genes were subjected to transcription factor target enrichment analysis using the Chea-background and Transfac database (downloaded from EnrichR \[[@bib6]\]), as described previously ([@bib20]).

Extracellular field potential recordings (MEA assay) {#s4-12}
----------------------------------------------------

For MEA recordings, we used 6well-MEA arrays, which contain six independent culture chambers, separated by a macrolon ring (60--6 well MEA 200/30 iR-Ti-rcr, Multichannel Systems, Germany). Inside each well, there is a field of nine electrodes with an internal reference electrode ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). The 6well-MEA arrays were prepared by pipetting 5 μl fibronectin solution (100 μg/mL, BD Biosciences) and incubated at 37°C for at least 1 hr. iPSC-CMs were dissociated using 0.025% trypsin for 5 min at 37°C and seeded onto prepared MEA plates using 5 μl of cell suspension in StemPro34 medium and then incubated at 37°C/5% CO2. The day after the cells were covered with 200 µL of StemPro34 media. MEA recordings were performed once the cells started to beat again (5--7 days). Field potentials of spontaneously beating cardiomyocytes were recorded using a high-resolution Micro Electrode Array (MEA) recording system (MEA60 system, Multi Channel Systems, Reutlingen, Germany, <http://www.multichannelsystems.com>) at 37°C. The baseline steady state was achieved following an equilibration period of about 15 min in vehicle medium (StemPro34 media). The tested drugs (E4031 and Sotalol, Sigma) were then added directly to each well. Dose-response experiments were performed with the following sequence: drugs were diluted in 200 μL of StemPro34 media; increasing concentrations of drug were added to a well of the MEA array in a cumulative manner; the FPD recordings were started 3 min after application of a given concentration of a drug, a timing that was found optimal to achieve steady-state changes; FPD recordings were then performed for two additional minutes. Each drug was tested in at least three different wells. Raw MEA data were acquired using QT-Screen Lite and MC-Rack softwares (Multi Channel Systems, Reutlingen, Germany). The data were then exported on QT-Analyzer Software to analyze the field potential duration and the inter-beat interval (Multi Channel Systems, Reutlingen, Germany). Parameters were averaged on the 2 min recordings. Inter-beat interval (in ms) was used to calculate the instantaneous beat rate. To account for the dependency between repolarization rate and the beating rate, FPD was firstly adjusted using the popular Bazett's formula (adjustedFPD = rawFPD / RR1/2). We however found that, as expected, this formula was associated with an important over-correction thus supporting the need for an alternative adjustment formula according to Funck-Brentano et al. ([@bib12]) ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}, panel A). We thus plotted the FPD / inter-beat-interval pairs recorded at various beating rates under baseline conditions. The following equation with the same dimension as a Bazett's formula: adjustedFPD = rawFPD / RRα, where alpha is a regression parameter, was applied to raw data in order to have a new estimate of the correction factor and results in appropriate corrections of FPD ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}, panel B).

Cells were considered as developing arrhythmias in response to sotalol as they presented ectopic beats or spontaneous beating rates became irregular.

Patch clamp recordings {#s4-13}
----------------------

hiPSC-derived embryoid bodies were enzymatically dissociated into single cardiomyocytes and plated on matrigel-coated glass coverslips. The action potential of cardiomyocytes was assessed in the current-clamp mode using whole-cell patch-clamp technique with a HEKA EPC10 amplifier and Pulse/PulseFit software (HEKA, Germany). Pipette solution consisted of: 110 mM potassium aspartate, 20 mM KCl, 10 mM HEPES, 1 mM MgCl2, 0.1 mM ATP (disodium salt), 5 mM ATP (magnesium salt), 5 mM phosphocreatine (disodium salt) and 1 mM EGTA (pH 7.2). The external bath solution contained 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 10 mM D-glucose, 1 mM CaCl2 and 10 mM HEPES (pH 7.4). hiPSC-CMs were perfused with either control or sotalol-containing Tyrode\'s solution for 5 min. The whole-cell condition was then reached. A hyperpolarization current (−30 pA) was applied to silence the spontaneous automaticity. The AP recording was then performed with a train of current pulse injection (1000 pA, 5 ms) at 0.5 Hz steady pacing. The assay was performed at 37°C and finished within 30 min upon the drug perfusion.

Statistical analysis {#s4-14}
--------------------

All analyses were performed using Prism 6.0 (GraphPad, La Jolla, CA). Continuous data are presented as Mean ± SEM. A p-value≤0.05 was considered significant. Continuous variables were compared using non-parametric Mann-Whitney test and binary variables were tested using Chi-square or exact Fisher's test as appropriate. For the in vivo investigations, we planned to identify 20 extreme responders to sotalol (i.e., 10 with high response defined by a deltaQTcf \>35 ms and 10 with low response defined by a deltaQTcf \<5 ms, therefore defining a minimal difference of 30 ms between groups). We then anticipated that this in vivo difference will be reproduced in vitro with a reduction by 33%. We thus determined that this sample size will give 80% power to demonstrate a difference of 20 ms between groups, with a standard error of 15 ms and an alpha-error risk of 0.05 (nQuery Advisor version 4.0).

Responses to drugs, as measured in vitro, were normalized to baseline values and expressed as changes to baseline to account for inter-line variability. All recorded data were analyzed. A two-way analysis of variance with repeated measures was performed to analyze response to sotalol. Sotalol concentrations define the first factor and the sensitivity group the second factor. Individual comparisons were performed when the overall analysis was significant. Dose response curves were built to estimate EC50 using the Hill equation.

Acknowledgements {#s5}
================

We thank the Biotrial core lab. This work was funded by the Cellectis Company. JH and RI are supported by NIH P50 GM071558 and GM54508 and U54 HG008098.

Funding Information
===================

This paper was supported by the following grants:

-   http://dx.doi.org/10.13039/100000002National Institutes of Health P50 GM071558 to Jens Hansen, Ravi Iyengar.

-   http://dx.doi.org/10.13039/100000002National Institutes of Health GM54508 to Jens Hansen, Ravi Iyengar.

-   http://dx.doi.org/10.13039/100000002National Institutes of Health U54 HG008098 to Jens Hansen, Ravi Iyengar.

-   Cellectis Company Research subvention to Jean-Sébastien Hulot.

Additional information {#s6}
======================

SR: Current or former employee of the Cellectis Company.

MW: Current or former employee of the Cellectis Company.

YV: Current or former employee of the Cellectis Company.

CD: Current or former employee of the Cellectis Company.

The other authors declare that no competing interests exist.

FS, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article.

JH, Analysis and interpretation of data, Drafting or revising the article.

C-WK, Acquisition of data, Analysis and interpretation of data.

IK, Acquisition of data, Drafting or revising the article.

CF-B, Analysis and interpretation of data, Drafting or revising the article.

LG, Acquisition of data, Analysis and interpretation of data.

SS, Acquisition of data, Drafting or revising the article.

SR, Acquisition of data, Drafting or revising the article.

MW, Acquisition of data, Drafting or revising the article.

YV, Acquisition of data, Contributed unpublished essential data or reagents.

CD, Conception and design, Contributed unpublished essential data or reagents.

J-ES, Analysis and interpretation of data, Drafting or revising the article.

DJ, Acquisition of data, Drafting or revising the article.

NZ, Acquisition of data, Drafting or revising the article.

RL, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article.

RI, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article.

RJH, Conception and design, Analysis and interpretation of data, Drafting or revising the article.

J-SH, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article.

Clinical trial registration clinicaltrials.gov NCT01338441.

Human subjects: The protocol was approved by local institutional ethics committee (CPP Ile de France XI 11-015 & Afssaps A110094-37) and all subjects gave their written informed consent for participation to the study.

10.7554/eLife.19406.022

Decision letter

Rossant

Janet

Hospital for Sick Children

,

Canada

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Modeling susceptibility to drug-induced long QT with a panel of subject-specific iPS cells\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Janet Rossant as the Senior Editor and Reviewing Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Stillitano and colleagues present an interesting translational study examining the ability of patient-specific iPS cells to report patient-specific responses to drug-induced long QT syndrome. This cardiotoxicity has led to multiple drug withdrawals as well as mandated safety testing for all new compounds seeking FDA approval. The authors have performed a clinical study in which they exposed volunteers to sotalol and measured changes in the electrocardiographic QT interval. They found that the patients exhibit a wide range of QTc responses. They then studied the extremes -- high sensitivity and low sensitivity to sotalol. They generated patient specific iPS cell lines from the low and high sensitivity patients and differentiated them to cardiomyocytes, whose electrical properties were studied using a microelectrode array system. The authors found evidence that the adjusted field potential duration (aFDP), an in vitro surrogate for the QTc interval in the ECG segregated with the low and high sensitivity samples as assessed clinically. These findings support the hypothesis that iPSC-CMs can be used to report patient-specific responses to QT prolonging drugs. In addition, the authors did genomic analysis comparing high and low sensitivity samples finding some variability in SNPs. In addition, transcriptome analysis identified changes in expression levels of genes associated with cardiac repolarization comparing high and low sensitivity samples which is intriguing. The manuscript has several strengths. This is the first attempt to do such a prospective clinical trial rigorously testing iPSC-CM technology, and it addresses problem that is highly relevant for drug development, unanticipated drug-induced QT prolongation. The number of lines tested and characterized is substantial given the extent of analysis involved.

Essential revisions:

While the reviewers were impressed with the number of volunteers analyzed and the depth of the analysis, they had several concerns that raised questions about the validity of the results. Most importantly, they were concerned that the measurements of QT intervals were not undertaken using the most accurate and commonly accepted methodology, based on the example in [Figure 1E](#fig1){ref-type="fig"}. For the high sensitivity example, the before measurement excluded the U wave and the after measurement includes the U wave thus extending the measured QT interval inappropriately in the post-sotalol measurement. Although there is not uniform consensus on QT interval measurement approaches, choosing the precordial wave with the largest T wave amplitude and variably including U waves is a potential problem that shakes confidence in the subsequent study that is absolutely dependent on the accuracy of these measurements. These measurements need to be substantiated.

Secondly, there was some concern that variability in cardiac differentiation efficiency among iPS lines could have influenced results. What measurements of iPSC-CM quality and purity were made routinely given that differentiation of different iPSC lines can yield different purity of CMs? This is a critical question since techniques taking whole preparations such as gene expression studies could be substantially impacted by contaminating cell types, e.g. 10% CMs from one line vs. 90% CMs from another line would not be expected to allow easy comparison of CM gene expression. This question is particularly raised because of the remarkable variability in various cardiac ion channel genes seen in [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}, with some lines show 10-20 fold differences in expression.

Third, the authors have found no differential response in the cells to E4031 (pure hERG blocker). As the primary effect of sotalol is, as stated by the authors themselves, hERG inhibition, why did their correlation between QTc and drug effects not work for E4031 as well? This needs to be discussed.
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Author response

Essential revisions:

While the reviewers were impressed with the number of volunteers analyzed and the depth of the analysis, they had several concerns that raised questions about the validity of the results. Most importantly, they were concerned that the measurements of QT intervals were not undertaken using the most accurate and commonly accepted methodology, based on the example in [Figure 1E](#fig1){ref-type="fig"}. For the high sensitivity example, the before measurement excluded the U wave and the after measurement includes the U wave thus extending the measured QT interval inappropriately in the post-sotalol measurement. Although there is not uniform consensus on QT interval measurement approaches, choosing the precordial wave with the largest T wave amplitude and variably including U waves is a potential problem that shakes confidence in the subsequent study that is absolutely dependent on the accuracy of these measurements. These measurements need to be substantiated.

We fully agree with this comment and we apologize as [Figure 1E](#fig1){ref-type="fig"} was indeed not submitted in its appropriate version. [Figure 1E](#fig1){ref-type="fig"} which was initially provided was mistakenly taken from a working version of the figure. We apologize for this inattention. The revised [Figure 1E](#fig1){ref-type="fig"} now shows typical ECG recordings in a high-sensitive and a low-sensitive subject. As detailed in the Methods section, we were indeed extremely careful in using highly accurate and standardized measurements of QT interval. A specific operating procedure was developed for ECG recordings, collections, transfer and analyses. The three consecutive complexes used for the measurements of the intervals were selected in periods with stable heart rate, stable baseline, absence of artifacts and U waves either absent or well differentiated from T-waves. Measurements were then performed using the tangent method by an investigator blindly of drug administration. Importantly, all ECG and measurements were reviewed by another cardiologist (still blinded of drug administration). As an extended example, we here provide the complete ECG recording and caliper positions (raw data, low resolution) for the high-s subject (baseline evaluation). All other ECG were recorded and measured in the same conditions (available on request).

The Methods section "ECG recording and analysis" has been updated accordingly.10.7554/eLife.19406.021Author response image 1.**DOI:** [http://dx.doi.org/10.7554/eLife.19406.021](10.7554/eLife.19406.021)

Secondly, there was some concern that variability in cardiac differentiation efficiency among iPS lines could have influenced results. What measurements of iPSC-CM quality and purity were made routinely given that differentiation of different iPSC lines can yield different purity of CMs? This is a critical question since techniques taking whole preparations such as gene expression studies could be substantially impacted by contaminating cell types, e.g. 10% CMs from one line vs. 90% CMs from another line would not be expected to allow easy comparison of CM gene expression. This question is particularly raised because of the remarkable variability in various cardiac ion channel genes seen in [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}, with some lines show 10-20 fold differences in expression.

We agree that inter-line variability in the efficiency of differentiation has been reported. Therefore, we systematically performed cardiac troponin T (cTNT^+^) Flow Cytometry in all iPSC-CM lines at day 25 of differentiation. We found an average of 47.8±19.9% cTNT+ cells. Importantly, after unblinding, we did not observe any differences between iPSC lines from the high-S vs. low-S groups (49.2±24.4% vs. 46.7±17.3% respectively, p=0.42). This has been added to the Results section (subsection "Derivation and differentiation of iPSCs into cardiomyocytes", last paragraph).

For measurements of iPSC-CMs quality, each line was tested for the presence of key CMs identity markers (sarcomeric proteins troponin T (cTnT), α-actinin and for the gap-junction protein connexin 43 (Cx43)) by immunostaining. A representative image is reported in [Figure 2A](#fig2){ref-type="fig"}. The MEA recordings were performed on a layer of iPSC-CMs that had spontaneous beating activity and had measurable field potential duration (FPD) as they developed contact with the electrodes. It seems unlikely that contaminating cell types would have influenced these results. In addition, patch clamp experiments were performed at the cell level on two different couples of iPSC-CM lines from each group (low-S and high-S) and confirmed the MEA results (see previous and new [Figure 4](#fig4){ref-type="fig"}). Finally, our gene expression studies were indeed performed on whole preparations because of challenges in enriching preparations in derived cardiomyocytes. For our transcriptomic study, we thus decided to use a prior knowledge based approach (on cardiac repolarization / LQTS neighborhood; based on a previously published methodology) to identify signals that are specifically coming from cardiomyocytes in these preparations. Indeed, a direct neighbor of a LQTS gene is anticipated to be cardiomyocyte specific. The expression of cardiac ion channel genes indeed appears variable ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}) but was similar between both groups (Low-S and high-S), as also further confirmed in our transcriptomic analysis ([Figure 5A](#fig5){ref-type="fig"} and Results section, subsection "Dysregulation of downstream regulators of cardiac ion channels"). For all of these reasons, we think we have limited the influence of variability in cardiac differentiation efficiency among iPS lines on our results. Our multiple investigations did not indicate a systematic bias favoring one group as compared to the other.

Third, the authors have found no differential response in the cells to E4031 (pure hERG blocker). As the primary effect of sotalol is, as stated by the authors themselves, hERG inhibition, why did their correlation between QTc and drug effects not work for E4031 as well? This needs to be discussed.

We thank the reviewers and editors for this comment. As pointed out, E-4031 is an experimental drug that is a selective hERG channel blocker whereas sotalol is a clinically used drug that is a non-selective competitive β-adrenergic receptor blocker with additional Class III antiarrhythmic properties by its inhibition of potassium channels. We found that trends in response to E-4031 (both for EC50 and maximal effect) were in the same direction than with sotalol but these trends did not reach statistical significance. The two compounds differ in their pharmacological characteristics in terms of inhibition potency and target selectivity. First, as compared to sotalol, E-4031 is a more potent hERG blocker with an IC~50~ value reported to be in the range of 10-100nM (vs. 10-50 µM for sotalol) and presents a very steep concentration-response effect (as observed in our lines, Figure 2---figure supplement 4C). It is thus possible that subtle differences in the susceptibility to develop prolonged cardiac repolarization in response to a given drug cannot be fully revealed when using a very potent inhibitor such as E-4031. Second, sotalol is thought to primarily prolong cardiac repolarization through hERG inhibition but sotalol can also affect other cardiac repolarization components. Our own transcriptomic results indicate that higher susceptibility to diLQT was associated with significant changes in expression of genes related to the regulation of ion channels homeostasis while the expression of cardiac ion channels (including hERG) was similar between both groups. A direct or indirect effect of sotalol on these components (in addition to its hERG effect) could explain the apparently discrepant results obtained with E-4031. This hypothesis would however deserve further investigations. The discussion has been corrected accordingly.

[^1]: These authors contributed equally to this work.

[^2]: \*Tested in originating fibroblast cell lines.

[^3]: ^†^As found in originating fibroblasts.
